CN110257506B - Polymorphism detection kit and method for hypertension accurate medication related gene - Google Patents

Polymorphism detection kit and method for hypertension accurate medication related gene Download PDF

Info

Publication number
CN110257506B
CN110257506B CN201910614761.9A CN201910614761A CN110257506B CN 110257506 B CN110257506 B CN 110257506B CN 201910614761 A CN201910614761 A CN 201910614761A CN 110257506 B CN110257506 B CN 110257506B
Authority
CN
China
Prior art keywords
labeled
reaction solution
ace
gene
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910614761.9A
Other languages
Chinese (zh)
Other versions
CN110257506A (en
Inventor
尹华立
裘惠良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Meilian Medical Examination Institute Co ltd
Hangzhou Qianji Biotechnology Co ltd
Original Assignee
Hangzhou Meilian Medical Co ltd
Hangzhou Qianji Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Meilian Medical Co ltd, Hangzhou Qianji Biotechnology Co ltd filed Critical Hangzhou Meilian Medical Co ltd
Priority to CN201910614761.9A priority Critical patent/CN110257506B/en
Publication of CN110257506A publication Critical patent/CN110257506A/en
Application granted granted Critical
Publication of CN110257506B publication Critical patent/CN110257506B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to the technical field of biological medicines, in particular to a kit and a method for detecting polymorphism of genes related to accurate administration of hypertension. The kit comprises a reaction solution I, a reaction solution II and a reaction solution III. The reaction solution I comprises a PCR buffer system and enzyme, the reaction solution II comprises ACE, CYP2D6 and ADRB1 gene detection primers and corresponding fluorescent probes, and the reaction solution III comprises NPPA, AGTR1, CYP3A5 and CYP2C9 gene detection primers and corresponding fluorescent probes. The kit and the method can detect the polymorphism of the gene related to clinical 5-class antihypertensive requirements quickly, sensitively and characteristically.

Description

Polymorphism detection kit and method for hypertension accurate medication related gene
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a kit and a method for detecting polymorphism of genes related to accurate administration of hypertension.
Background
Essential hypertension is one of the most common chronic diseases and is an important risk factor for cardiovascular diseases such as coronary heart disease, cerebral apoplexy and the like, and a large number of researches prove that essential hypertension is mainly influenced by both genetic factors and environmental factors. The blood pressure lowering drugs commonly used in clinic at present comprise diuretics, beta adrenoceptor blockers, calcium antagonists, ACE inhibitors, angiotensin II receptor antagonists and alpha adrenoceptor blockers, however, the drugs for treating hypertension in clinic have quite common individual response differences, mainly because of genetic variations of drug-related drug metabolic enzymes and receptors.
CYP2D6 only accounts for 1-2% of total CYP in liver, but the medicines catalyzed and metabolized by the CYP2D6 are more than 80, and the activity of CYP2D6 of different individuals can be different by 1000 times at most. The most common polymorphism in the chinese population is CYP2D6 x 10, and about 51.6% of the chinese population carry this genetic variation. This polymorphism results in a decrease in the enzymatic activity of CYP2D6 and is extremely unstable, thereby affecting drug metabolism.
The beta adrenergic receptor belongs to the superfamily of G protein-coupled receptors and is encoded by the ADRB1 gene, and the gene has polymorphism. Research shows that ADRB1 gene G1165C polymorphism is related to hypertension drug treatment, and after metoprolol, carvedilol and the like are used for treatment, C1165 homozygote individuals have higher effective rate.
Angiotensin converting enzyme is a key enzyme of renin-angiotensin system, and is coded by ACE gene, which is positioned in 3 zone of 2 region of long arm of 17 # chromosome and 21kb in sequence length. The ACE gene has a plurality of genetic polymorphisms, wherein polymorphism of an Alu insertion fragment (I) and a deletion fragment (D) of 287bp existing in a 16 th intron is related to hypertension drug treatment, research shows that the curative effect of a DD homozygote individual using benazepril and fosinopril is obvious, the curative effect of a II homozygote individual using enalapril and imidapril is obvious, and the curative effect of an ID heterozygote individual using angiotensin inhibitor drugs is effective.
The novel diuretic indapamide (Erbborn, indapamide) is marketed, so that the treatment status of the diuretic in hypertension is improved, and the novel diuretic indapamide is characterized in that the common dosage only shows slight diuretic effect and mainly shows vasodilatation effect, the effective rate for reducing blood pressure is about 80 percent, and the side effect of metabolic abnormality of the traditional diuretic is not existed, so that the novel indapamide is widely applied clinically. Atrial Natriuretic Peptide Precursor A (NPPA) is a "candidate gene" for studying genetic susceptibility to various diseases, is located on human chromosome 1p36, and encodes a precursor of ANP. ANP acts as a diuretic to control the balance of extracellular fluid volume and electrolytes, and increasing ANP levels can cause hypotension. Research shows that ANP (and NPPA gene) is related to various cardiovascular and cerebrovascular diseases, such as cerebral apoplexy, heart failure, left atrial hypertrophy, hypertension and the like. NPPA G664A is a single nucleotide mutation (G/A) located in exon 1 of the gene, resulting in a change of amino acid 7 of the ANP precursor protein to methionine, resulting in reduced ANP activity.
Cytochrome oxidase P450 (CYP 2C 9) is an important drug metabolizing enzyme in the human liver, accounting for about 20% of the total amount of CYP enzymes in the human liver. The distribution of CYP2C9 allele has obvious population, ethnicity and geographical difference, in Chinese population, the main mutant gene is CYP2C9 x 3, which is the mutation of A > C at 1075 th site of 7 th exon, resulting in the mutation of 359 nd isoleucine on CYP2C9 polypeptide chain into leucine (Ile 359> Leu 359), and the allele frequency is 1.0-3.5%. Losartan, irbesartan and other sartan are common blood pressure lowering drugs, are effective angiotensin receptor antagonists and are mainly metabolized by CYP2C9, and researches show that the sartan drugs are mainly metabolized by CYP2C9 in vivo, and the mutation of polymorphic CYP2C9 x 3 causes the remarkable reduction of enzyme activity, the increase of toxicity and the reduction of curative effect. Clinical studies show that CYP2C9 x 3 mutation can cause the reduction of the blood pressure reducing effect of losartan; the CYP2C9 x 3 mutation increases the blood concentration of valsartan and irbesartan, resulting in an enhanced hypotensive effect of valsartan and irbesartan. Therefore, when selecting a sartan drug for a hypertensive patient, CYP2C9 should be first subjected to genetic testing, and a sartan drug should be selected based on the genotype of CYP2C9 x 3.
Angiotensin II receptor antagonists (Angiotensin II receptor antagonists) are a class of drugs acting on the renin-Angiotensin system, and are mainly used for the treatment of hypertension, diabetic nephropathy and congestive heart failure. The type I Angiotensin II receptor (Angiotensin II receptor type 1, agtr1) is a receptor of Angiotensin II (Angiotensin, ang II), which is mainly distributed on vascular smooth muscle cells and mediates most of the biological effects of Ang II. It is a component of the renin-angiotensin system (RAS) and has important implications for the development of hypertension and for drug therapy. The human AGTR1 gene is located at 3q21-25, and contains only 1 exon, without intron region. The frequency of T573C, A1166C and A1062G substitution is the highest in AGTR1 gene polymorphism, and patients with the A1166C genotype show more significant blood pressure response when losartan and candesartan are used. The drug sensitivity of hypertensive patients to angiotensin II receptor blockers (such as losartan, irbesartan, telmisartan, etc.) is as follows: the drug sensitivity of the A1166A patient is normal, and the conventional dosage is recommended; A1166C patient has high drug sensitivity, and the dosage is recommended to be reduced; patients with C1166C have increased drug sensitivity and lower doses are recommended.
Calcium antagonists are chemical agents that lower blood pressure by blocking calcium channels. It can selectively inhibit Ca 2+ Enters into cells through calcium channels on cell membranes, relaxes vascular smooth muscle by expanding blood vessels and negative muscle strength, reduces peripheral vascular resistance, and thus has the function of reducing blood pressure. Cytochrome P450 (CYP) is a large class of drug metabolizing enzymes involved in the metabolism of many drugs, xenobiotics and endogenous substances. CYP3A5 is predominantly expressed in the liver and small intestine of adults with significant polymorphisms in its expression. Mutations in the CYP3A5 gene are the most important cause of differences in enzyme activity, with CYP3A5 x 3 being at intron3 (6959A)>G) The mutation(s) causes variable cleavage, resulting in an unstable protein, so that the mutagenized homozygous individual, i.e. the person carrying the gene CYP3A5 x 3/' 3, does not express CYP3A5. Research shows that calcium antagonist drugs are greatly influenced by CYP3A5 x 3 gene polymorphism, and patients with mutant genotypes have increased toxic and side effects of the drugs.
The detection methods of gene polymorphism are many, and the most common methods comprise a sequencing method, DHPLC, PCR-SSCP/RFLP, ARMS, taqman PCR, ME-PCR, gene chip and the like. The methods are complex to operate, long in detection period, and difficult to control, have a plurality of factors influencing detection results, and are difficult to meet the requirements of clinical reagent detection, and are only carried out in the field of scientific research at present.
Disclosure of Invention
The invention aims to provide a kit and a method for rapidly, accurately and systematically detecting hypertension medication related gene polymorphism aiming at the defects of the prior art.
In order to solve the problems, the invention adopts the following technical scheme:
a kit for detecting polymorphism of genes related to accurate medication of hypertension comprises a reaction liquid I, a reaction liquid II, a reaction liquid III, a positive control substance and a negative control substance. The reaction solution I comprises a PCR buffer system and enzyme, the reaction solution II comprises ACE, CYP2D6 and ADRB1 gene detection primers and corresponding fluorescent probes, the reaction solution III comprises NPPA, AGTR1, CYP3A5 and CYP2C9 gene detection primers and corresponding fluorescent probes, the positive control is a heterozygous plasmid of seven genes of ACE, CYP2D6, ADRB1, NPPA, AGTR1, CYP3A5 and CYP2C9, and the negative control is Tris salt without target genes.
The reaction solution I comprises 10 × Taq buffer I,5 × Taq buffer II, hotstart Taq enzyme, UDG enzyme, dNTP, dUTP and an enhancer; the 10 × taq buffer I comprises 200mM Tris-HCl (pH8.4), 200mM KCl,100mM (NH) 4 ) 2 SO 4 ，15mM MgCl 2 (ii) a The 5 × taq buffer II comprises 20mM Mg SO 4 The enhancer is a mixture comprising 0.5M betaine, 1% (V/V) formamide, 3% (V/V) glycerol and 0.2mg/ml BSA.
The reaction solution II contains ACE, CYP2D6 and ADRB1 detection primers and corresponding probes as follows:
ACE F1：TTTCTCTAGACCTGCTGCCTATAC
ACE R1：AGCTCAGAGAATTTCAGAGCTG
ACE P: CTGCTGCCTATACAGTCACTTTTATGTGG, end 5 labeled ROX and end 3 labeled BHQ2.
D6 F1：CCTCCCTCACCTGGTCGAAGC
D6 R1：TTCCTGCTCCTGGTGGACCTG
D6 P: CTGCACGCTACTCACCAGGCCC, end 5 labeled FAM, end 3 labeled BHQ1.
B1 F1：GCCTTCAACCCCATCATCT
B1 R1：GTCGTCGTCGTCGTCCGA
B1 P: TTCCAGCGACTGCTCTGCT, 5-end labeled HEX, 3-end labeled BHQ1.
The reaction solution II comprises the following detection primers in proportion: ACE F1: ACE R1=2pmol:20pmol; d6 F1: d6 R1=30pmol:3pmol; b1 F1: b1 R1=2pmol:20pmol; the amounts of the three detection probes added were all 5pmol.
The reaction solution III contains NPPA, AGTR1, CYP3A5, CYP2C9 detection primers and corresponding probes as follows:
R1 F1：TGAGTGACATGTTCGAAACC
R1 R1：CAGCCGTCATCTGTCTAATGC
R1P: CAAATGAGCATTAGCTACTTTTCAGA, end 5 labeled ROX and end 3 labeled BHQ2.
PA F1：GACACAAATGCAGCAGAGAC
PA R1：AGGATGGGCACACTCATAC
PA P: CTGTTATCTTCAGTACTGCAAAGAGAAC, 5-end labeled FAM, 3-end labeled BHQ1.
A5 F1：GAGAGTGGCATAGGAGATAC
A5 R1：CACAGCAAGAGTCTCACACAG
A5 P: TGTCTTTCAATATCTCTTCCCTGTTTG, end 5 is labeled CY5 and end 3 is labeled BHQ3.
C9 F1：ATCAGCTAAAGTCCAGGAA
C9 R1：GAAACAAACTTACCTTGGGAAT
C9 P: CGAGGTCCAGAGATACATTGACC, end 5 labeled HEX, and end 3 labeled BHQ1.
The reaction solution III contains the following detection primers in proportion: R1F 1: r1=4pmol:40pmol; PA F1: PA R1=3pmol:30pmol; a5 F1: a5 R1=2pmol:20pmol; c9 F1: c9 R1=40pmol:4pmol, and the amounts of the four detection probes were 5pmol each.
A method for detecting polymorphism of related genes of accurate medication of hypertension comprises the following detection steps:
1) The reaction solution I was mixed in an amount of 19 ul: 2ul of reaction liquid II is prepared into an amplification detection reagent I; the reaction solution I was measured in 19 ul: 2ul of reaction solution III is prepared into an amplification detection reagent II.
2) Absorbing 4ul of each DNA of a sample to be detected, respectively adding the DNA into the amplification detection reagent I and the amplification detection reagent II, and respectively mixing uniformly.
3) And placing the reaction tube with the DNA-added amplification detection reagent I and the amplification detection reagent II in a real-time fluorescent PCR instrument for PCR amplification detection.
4) The real-time fluorescent PCR amplification program was set up as follows:
Figure BDA0002123565650000051
a method for detecting polymorphism of related genes of accurate medication of hypertension is disclosed, wherein the interpretation of results of 7 genotypes is as follows:
Figure BDA0002123565650000052
Figure BDA0002123565650000061
compared with the prior art, the invention has the following characteristics:
1) The invention provides a kit and a method for detecting polymorphism of related genes of five major antihypertensive drugs, which can effectively guide clinical application of mainstream antihypertensive drugs. Compared with the existing products on the market, the coverage is more complete.
2) The invention adopts a single probe combined with a melting curve method to detect gene polymorphism, and simultaneously adopts two-tube multiplex PCR reaction to detect 7 related gene polymorphisms of the hypertension drug, thereby having the advantages of rapidness, high sensitivity, strong specificity, simple method, accurate detection result and the like.
3) The kit can detect polymorphism of 10pg genome DNA.
Drawings
FIG. 1 shows the result of detecting polymorphism at CYP2D6 x 10 locus.
FIG. 2 shows the result of detecting ADRB1 (1165G > C) site polymorphism.
FIG. 3 shows the detection results of ACE (I/D) site polymorphism.
FIG. 4 shows the result of detecting the polymorphism of NPPA (664G > A) site.
FIG. 5 shows the result of detecting polymorphism at CYP2C9 x 3 site.
FIG. 6 shows the result of detecting polymorphisms of AGTR1 (1166A > C) sites.
FIG. 7 shows the results of detecting polymorphisms at CYP3A5 x 3 locus.
Detailed Description
The invention is further described below with reference to the accompanying drawings.
Example 1: design of primers and probes of hypertension individualized medication related gene polymorphism detection kit
Detection probes and primers are designed according to seven gene related detection sites of ACE (rs 4646994), CYP2D6 (rs 1065852), ADRB1 (rs 1801253), NPPA (rs 5065), AGTR1 (rs 5186), CYP3A5 (rs 776746) and CYP2C9 (rs 56165452), and related sequences are as follows:
ACE F1：TTTCTCTAGACCTGCTGCCTATAC
ACE R1：AGCTCAGAGAATTTCAGAGCTG
ACE P: CTGCTGCCTATACAGTCACTTTTATGTGG, end 5 marked ROX and end 3 marked BHQ2.
D6 F1：CCTCCCTCACCTGGTCGAAGC
D6 R1：TTCCTGCTCCTGGTGGACCTG
D6 P: CTGCACGCTACTCACCAGGCCC, end 5 labeled FAM, end 3 labeled BHQ1.
B1 F1：GCCTTCAACCCCATCATCT
B1 R1：GTCGTCGTCGTCGTCCGA
B1 P: TTCCAGCGACTGCTCTGCT, end 5 labeled HEX, and end 3 labeled BHQ1.
R1 F1：TGAGTGACATGTTCGAAACC
R1 R1：CAGCCGTCATCTGTCTAATGC
R1P: CAAATGAGCATTAGCTACTTTTCAGA, end 5 marked ROX and end 3 marked BHQ2.
PA F1：GACACAAATGCAGCAGAGAC
PA R1：AGGATGGGCACACTCATAC
PA P: CTGTTATCTTCAGTACTGCAAAGAGAAC, 5-end labeled FAM, 3-end labeled BHQ1.
A5 F1：GAGAGTGGCATAGGAGATAC
A5 R1：CACAGCAAGAGTCTCACACAG
A5 P: TGTCTTTCAATATCTCTTCCCTGTTTG, end 5 is labeled CY5 and end 3 is labeled BHQ3.
C9 F1：ATCAGCTAAAGTCCAGGAA
C9 R1：GAAACAAACTTACCTTGGGAAT
C9 P: CGAGGTCCAGAGATACATTGACC, end 5 labeled HEX, and end 3 labeled BHQ1. Example 2: preparation of hypertension individualized medication related gene polymorphism detection kit
The reaction solution I is a mixture containing 10 × Taq buffer I,5 × Taq buffer II, hotstart Taq enzyme, UDG enzyme, dNTP, dUTP and an enhancer, and provides a buffer system for efficient amplification for real-time fluorescent PCR. Wherein the 10 × taq buffer I comprises 200mM Tris-HCl(pH8.4)，200mM KCl，100mM(NH 4 ) 2 SO 4 ，15mM MgCl 2 (ii) a The 5 × taq buffer II comprises 20mM Mg SO 4 The enhancer is a mixture comprising 0.5M betaine, 1% (V/V) formamide, 3% (V/V) glycerol and 0.2mg/ml BSA.
Reaction solution II contains ACE, CYP2D6 and ADRB1 gene detection primers and corresponding fluorescent probes, wherein CE F1: ACE R1=2pmol:20pmol; d6 F1: d6 R1=30pmol:3pmol; b1 F1: b1 R1=2pmol:20pmol; the amount of the three detection probes added was 5pmol each.
The reaction solution III contains NPPA, AGTR1, CYP3A5, CYP2C9 gene detection primers and related fluorescent probes, wherein R1F 1: r1=4pmol:40pmol; PA F1: PA R1=3pmol:30pmol; a5 F1: a5 R1=2pmol:20pmol; c9 F1: c9 R1=40pmol:4pmol, and 5pmol for each of the four detection probes.
The positive control is a hybrid plasmid of seven genes of ACE, CYP2D6, ADRB1, NPPA, AGTR1, CYP3A5 and CYP2C 9.
The negative control is Tris salt without target gene.
Example 3: method for using hypertension individualized medication related gene polymorphism detection kit
1) And extracting the genome DNA in the sample to be detected.
2) The reaction solution I was mixed in an amount of 19 ul: 2ul of reaction liquid II is prepared into an amplification detection reagent I; the reaction solution I was mixed in an amount of 19 ul: 2ul of reaction solution III is prepared into an amplification detection reagent II.
3) And (3) sucking the DNA of the sample to be detected, the positive reference substance and the negative reference substance, respectively adding the DNA, the positive reference substance and the negative reference substance into the amplification detection reagent I and the amplification detection reagent II respectively, and uniformly mixing.
4) And placing the reaction tube of the amplification detection reagent I and the amplification detection reagent II which are added with the DNA into a real-time fluorescent PCR instrument for PCR amplification detection.
Wherein the amplification procedure is as follows:
Figure BDA0002123565650000081
Figure BDA0002123565650000091
interpretation criteria of results:
Figure BDA0002123565650000092
100 clinical blood samples were collected, genomic DNA was extracted using a commercial blood extraction kit, and then the kit of the present invention was used for detecting the relevant gene polymorphisms, and the sanger sequencing method was used for comparison, all of which were consistent.
Sequence listing
<110> Hangzhou Qianji Biotechnology Co., ltd
HANGZHOU BOXIN BIOTECHNOLOGY Co.,Ltd.
<120> polymorphism detection kit and method for related gene of accurate hypertension medication
<160> 21
<170> SIPOSequenceListing 1.0
<210> 1
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
tttctctaga cctgctgcct atac 24
<210> 2
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
agctcagaga atttcagagc tg 22
<210> 3
<211> 29
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ctgctgccta tacagtcact tttatgtgg 29
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
cctccctcac ctggtcgaag c 21
<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ttcctgctcc tggtggacct g 21
<210> 6
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ctgcacgcta ctcaccaggc cc 22
<210> 7
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
gccttcaacc ccatcatct 19
<210> 8
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
gtcgtcgtcg tcgtccga 18
<210> 9
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
ttccagcgac tgctctgct 19
<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
tgagtgacat gttcgaaacc 20
<210> 11
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
cagccgtcat ctgtctaatg c 21
<210> 12
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
caaatgagca ttagctactt ttcaga 26
<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
gacacaaatg cagcagagac 20
<210> 14
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
aggatgggca cactcatac 19
<210> 15
<211> 28
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
ctgttatctt cagtactgca aagagaac 28
<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
gagagtggca taggagatac 20
<210> 17
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
cacagcaaga gtctcacaca g 21
<210> 18
<211> 27
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
tgtctttcaa tatctcttcc ctgtttg 27
<210> 19
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
atcagctaaa gtccaggaa 19
<210> 20
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
gaaacaaact taccttggga at 22
<210> 21
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 21
cgaggtccag agatacattg acc 23

Claims (2)

1. A polymorphism detection kit for a gene related to accurate administration of hypertension is characterized by comprising a reaction liquid I, a reaction liquid II, a reaction liquid III, a positive control substance and a negative control substance; the reaction solution I comprises a PCR buffer system, a reinforcing agent and an enzyme, the reaction solution II comprises ACE, CYP2D6 and ADRB1 gene detection primers and corresponding fluorescent probes, the reaction solution III comprises NPPA, AGTR1, CYP3A5 and CYP2C9 gene detection primers and corresponding fluorescent probes, the positive control is a heterozygous plasmid of seven genes of ACE, CYP2D6, ADRB1, NPPA, AGTR1, CYP3A5 and CYP2C9, and the negative control is Tris salt without a target gene;
the reaction solution I comprises 10 Xtaq buffer I,5 Xtaq buffer II, hotspot Taq enzyme, UDG enzyme, dNTP, dUTP and an enhancer; the 10 × taq buffer I contains 200mM Tris-HCl,200mM KCl,100mM (NH) with pH8.4 4 ） 2 SO 4 ，15mM MgCl 2 (ii) a The 5 Xtaq buffer II contains 20mM Mg SO 4 The enhancer is a mixture containing 0.5M betaine, 1% (V/V) formamide, 3% (V/V) glycerol and 0.2mg/ml BSA;
the reaction solution II comprises the following detection primers and fluorescent probes:
ACE F1：TTTCTCTAGACCTGCTGCCTATAC
ACE R1：AGCTCAGAGAATTTCAGAGCTG
ACE P: CTGCTGCCTATACAGTCACTTTTATGTGG, end 5 labeled ROX, end 3 labeled BHQ2;
D6 F1：CCTCCCTCACCTGGTCGAAGC
D6 R1：TTCCTGCTCCTGGTGGACCTG
d6 P: CTGCACGCTACTCACCAGGCCC, end 5 labeled FAM, end 3 labeled BHQ1;
B1 F1：GCCTTCAACCCCATCATCT
B1 R1：GTCGTCGTCGTCGTCCGA
b1 P: TTCCAGCGACTGCTCTGCT,5 end labeled HEX,3 end labeled BHQ1;
the reaction solution III comprises the following detection primers and fluorescent probes:
R1 F1：TGAGTGACATGTTCGAAACC
R1 R1：CAGCCGTCATCTGTCTAATGC
R1P: CAAATGAGCATTAGCTACTTTTCAGA, end 5 labeled ROX, end 3 labeled BHQ2;
PA F1：GACACAAATGCAGCAGAGAC
PA R1：AGGATGGGCACACTCATAC
PA P: CTGTTATCTTCAGTACTGCAAAGAGAAC, end 5 labeled FAM, end 3 labeled BHQ1;
A5 F1：GAGAGTGGCATAGGAGATAC
A5 R1：CACAGCAAGAGTCTCACACAG
a5 P: TGTCTTTCAATATCTCTTCCCTGTTTG, end 5 marker CY5, end 3 marker BHQ3;
C9 F1：ATCAGCTAAAGTCCAGGAA
C9 R1：GAAACAAACTTACCTTGGGAAT
c9 P: CGAGGTCCAGAGATACATTGACC, end 5 labeled HEX, and end 3 labeled BHQ1.
2. The kit for detecting the polymorphism of the gene related to the accurate administration of hypertension according to claim 1, wherein the ratio of the detection primers in the reaction solution II is as follows: ACE F1: ACE R1=2pmol:20pmol; d6 F1: d6 R1=30pmol:3pmol; b1 F1: b1 R1=2pmol:20pmol; the addition amount of the three detection probes is 5pmol;
the proportion of the detection primers in the reaction solution III is as follows: R1F 1: r1=4pmol:40pmol; PA F1: PA R1=3pmol:30pmol; a5 F1: a5 R1=2pmol:20pmol; c9 F1: c9 R1=40pmol:4pmol, and 5pmol for each of the four detection probes.
CN201910614761.9A 2019-07-09 2019-07-09 Polymorphism detection kit and method for hypertension accurate medication related gene Active CN110257506B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910614761.9A CN110257506B (en) 2019-07-09 2019-07-09 Polymorphism detection kit and method for hypertension accurate medication related gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910614761.9A CN110257506B (en) 2019-07-09 2019-07-09 Polymorphism detection kit and method for hypertension accurate medication related gene

Publications (2)

Publication Number Publication Date
CN110257506A CN110257506A (en) 2019-09-20
CN110257506B true CN110257506B (en) 2023-04-07

Family

ID=67925228

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910614761.9A Active CN110257506B (en) 2019-07-09 2019-07-09 Polymorphism detection kit and method for hypertension accurate medication related gene

Country Status (1)

Country Link
CN (1) CN110257506B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110863042A (en) * 2019-10-11 2020-03-06 济南和合医学检验有限公司 Method for detecting hypertension related gene by using multiple PCR technology
CN111893174A (en) * 2020-07-23 2020-11-06 上海联吉医学检验所有限公司 Method for joint detection of cerebral apoplexy medication gene loci, primer group, probe group and kit thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013159085A1 (en) * 2012-04-20 2013-10-24 University Of Virginia Patent Foundation Compositions and methods for identifying and diagnosing salt sensitivity of blood pressure
CN108690876A (en) * 2016-08-25 2018-10-23 杭州百迈生物股份有限公司 Detect primer, probe and application, kit and the detection method of ACE gene pleiomorphisms
CN106755560B (en) * 2017-03-30 2020-03-27 德必碁生物科技（厦门）有限公司 Kit for detecting gene polymorphism of hypertension drug by multiple fluorescence PCR method
CN109457024A (en) * 2018-03-23 2019-03-12 杭州泰领生物技术有限公司 Shr gene polymorphism fluorescent PCR solubility curve detection kit and application
CN109355368A (en) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 A kind of kit and method of quick detection hypertension individuation medication gene pleiomorphism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
唐炳华，等.《分子生物学》.《分子生物学》.2017,第400页. *

Also Published As

Publication number Publication date
CN110257506A (en) 2019-09-20

Similar Documents

Publication Publication Date Title
US6525185B1 (en) Polymorphisms associated with hypertension
CN109082464B (en) Primer group and kit for detecting hypertension drug metabolism related genes
CN103789408B (en) The qualification of hypertension susceptible gene group
CN110257506B (en) Polymorphism detection kit and method for hypertension accurate medication related gene
CN111100929A (en) Kit for detecting polymorphism of drug-related gene for hypertension
CN108531578A (en) A kind of Primer composition and kit for detecting hypertension medication related gene
EP2307572B1 (en) Diagnostic polymorphisms for cardiac disease
Lai et al. CYP3A5* 3 and MDR-1 C3435T single nucleotide polymorphisms in six Chinese ethnic groups
JP2020120625A (en) Risk assessment method for non-alcoholic liver disease using single nucleotide polymorphism
JP5560456B2 (en) How to determine the side effects or efficacy of erlotinib
Gong et al. Polymorphisms of the angiotensin II type 1 receptor gene affect antihypertensive response to angiotensin receptor blockers in hypertensive Chinese
US8236497B2 (en) Methods of diagnosing cardiovascular disease
US8304190B2 (en) Pharmacogenomics of blood pressure lowering agents
KR101617612B1 (en) SNP Markers for hypertension in Korean
Eljali The genetics of risk in type 2 diabetes mellitus: does whole exome sequencing of pooled DNA identify population-specific risk alleles?
JP4041701B2 (en) Method for determining susceptibility to hypertension or proteinuria related diseases
WO2013189015A1 (en) Snp markers associated with polycystic ovary syndrome
CN1858243A (en) Method for predicting angiotonin II receptor agonist hypotensor medicine function and its use
JP2002238577A (en) Cerebral aneurysm-sensitive gene
CN101230392B (en) Method and reagent for predicting susceptibility of type 2 diabetes mellitus
WO2013035861A1 (en) Method for determining susceptibility to age-related macular degeneration, primer pair, probe, age-related macular degeneration diagnostic kit, therapeutic agent for age-related macular degeneration, and screening method for therapeutic agent for age-related macular degeneration
JP2004313168A (en) Nucleic acid molecule which can be used for gene diagnosis on susceptibility to depressor
CN1858241A (en) Method for predicting angiotonin II receptor agonist hypotensor function and use
CN1858242A (en) Method for predicting angiotonin II receptor agonist hypotensor medicine function and its use
WO2010014000A1 (en) Susceptibility markers for multiple sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220519

Address after: 311200 room 911, block C, no.198, Qidi Road, economic and Technological Development Zone, Xiaoshan District, Hangzhou City, Zhejiang Province

Applicant after: HANGZHOU QIANJI BIOTECHNOLOGY Co.,Ltd.

Applicant after: HANGZHOU MEILIAN MEDICAL EXAMINATION INSTITUTE Co.,Ltd.

Address before: 311200 room 911, block C, no.198, Qidi Road, economic and Technological Development Zone, Xiaoshan District, Hangzhou City, Zhejiang Province

Applicant before: HANGZHOU QIANJI BIOTECHNOLOGY Co.,Ltd.

Applicant before: HANGZHOU BOXIN BIOTECHNOLOGY Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: 311200 room 911, block C, no.198, Qidi Road, economic and Technological Development Zone, Xiaoshan District, Hangzhou City, Zhejiang Province

Applicant after: HANGZHOU QIANJI BIOTECHNOLOGY Co.,Ltd.

Applicant after: Hangzhou Meilian Medical Co.,Ltd.

Address before: 311200 room 911, block C, no.198, Qidi Road, economic and Technological Development Zone, Xiaoshan District, Hangzhou City, Zhejiang Province

Applicant before: HANGZHOU QIANJI BIOTECHNOLOGY Co.,Ltd.

Applicant before: HANGZHOU MEILIAN MEDICAL EXAMINATION INSTITUTE Co.,Ltd.

GR01 Patent grant
GR01 Patent grant